We are live on ! Find out more
KRTX

Karuna Therapeutics, Inc. Common Stock

Delisted

KRTX was delisted on the 15th of March, 2024.

246 hedge funds and large institutions have $7.02B invested in Karuna Therapeutics, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 37 funds opening new positions, 111 increasing their positions, 70 reducing their positions, and 37 closing their positions.

New
Increased
Maintained
Reduced
Closed

118% more call options, than puts

Call options by funds: $176M | Put options by funds: $80.7M

59% more repeat investments, than reductions

Existing positions increased: 111 | Existing positions reduced: 70

4% more capital invested

Capital invested by funds: $6.78B → $7.02B (+$242M)

0% more first-time investments, than exits

New positions opened: 37 | Existing positions closed: 37

1% less funds holding

Funds holding: 248246 (-2)

17% less funds holding in top 10

Funds holding in top 10: 1210 (-2)

Holders
246
Holders Change
-2
Holders Change %
-0.81%
% of All Funds
3.92%
Holding in Top 10
10
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-16.67%
% of All Funds
0.16%
New
37
Increased
111
Reduced
70
Closed
37
Calls
$176M
Puts
$80.7M
Net Calls
+$95.1M
Net Calls Change
+$53.1M

KRTX Hedge Fund Activity: Q1 2023 in Review

246 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Karuna Therapeutics, Inc. Common Stock (KRTX) for Q1 2023, worth a combined $7.02B — up 3.6% from $6.78B a quarter earlier.

Fund positioning in KRTX was balanced in Q1 2023: 37 funds opened new positions, 37 closed out, 111 added to existing stakes and 70 trimmed.

The largest buyer was Capital International Investors, adding an estimated $324M. The largest seller was Arch Venture Management, cutting an estimated $92.3M.

  • 246 institutional investors held Karuna Therapeutics, Inc. Common Stock (KRTX) as of Q1 2023, down from 248 in Q4 2022.
  • Funds reported $7.02B of Karuna Therapeutics, Inc. Common Stock stock for Q1 2023, up 3.6% quarter-over-quarter.
  • 37 funds opened new Karuna Therapeutics, Inc. Common Stock positions in Q1 2023 and 37 closed out, a net change of 0 holders.
  • The largest Karuna Therapeutics, Inc. Common Stock buyer in Q1 2023 was Capital International Investors, an estimated $324M added.
  • The largest Karuna Therapeutics, Inc. Common Stock seller in Q1 2023 was Arch Venture Management, an estimated $92.3M sold.

Based on aggregated 13F filings for Q1 2023.